Chunyan Wang

Shenyang, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Serplulimab combined with bevacizumab and chemotherapy as first-line treatment for recurrent or metastatic cervical cancer (ASTRUM-CC01): a phase II trial.

Serplulimab combined with bevacizumab and chemotherapy as first-line treatment for recurrent or metastatic cervical cancer (ASTRUM-CC01): a phase II trial.

Journal: Frontiers in immunology

Published: June 30, 2026

Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer.

Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer.

Journal: The New England journal of medicine

Published: October 15, 2025

Guideline for the management pathway and quality control of ovarian cancer diagnosis and treatment in county-level regions of China (2025 Edition).

Guideline for the management pathway and quality control of ovarian cancer diagnosis and treatment in county-level regions of China (2025 Edition).

Journal: Chinese medical journal

Published: July 31, 2025

Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.

Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial.

Journal: Nature communications

Published: April 21, 2025

Corrigendum to 'Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial' [Journal of the National Cancer Center 4 (2024) 135-141].

Corrigendum to 'Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial' [Journal of the National Cancer Center 4 (2024) 135-141].

Journal: Journal of the National Cancer Center

Published: March 05, 2025

Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.

Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.

Journal: Lancet (London, England)

Published: August 28, 2024

Age-specific performance of human papillomavirus E6/E7 mRNA assay versus cytology for primary cervical cancer screening and triage: community-based screening in China.

Age-specific performance of human papillomavirus E6/E7 mRNA assay versus cytology for primary cervical cancer screening and triage: community-based screening in China.

Journal: Frontiers in cellular and infection microbiology

Published: May 05, 2024

Clinical value of optical coherence tomography in the early diagnosis of cervical cancer and precancerous lesions: a cross-sectional study.

Clinical value of optical coherence tomography in the early diagnosis of cervical cancer and precancerous lesions: a cross-sectional study.

Journal: Frontiers in oncology

Published: April 28, 2024

Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial.

Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial.

Journal: Journal of the National Cancer Center

Published: December 07, 2023

Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study.

Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: October 24, 2023

Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.

Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.

Journal: JAMA oncology

Published: July 13, 2023

Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study.

Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study.

Journal: Frontiers in immunology

Published: January 11, 2023

Showing 1-12 of 28

Last Updated: 09/26/2026